Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Iradimed (IRMD) Invested Capital (2016 - 2025)

Iradimed (IRMD) has disclosed Invested Capital for 13 consecutive years, with $98.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Invested Capital rose 17.88% to $98.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $98.4 million, a 17.88% increase, with the full-year FY2024 number at $86.8 million, up 21.56% from a year prior.
  • Invested Capital was $98.4 million for Q3 2025 at Iradimed, up from $94.3 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $98.4 million in Q3 2025 to a low of $62.5 million in Q1 2022.
  • A 5-year average of $75.2 million and a median of $72.2 million in 2021 define the central range for Invested Capital.
  • Peak YoY movement for Invested Capital: dropped 3.06% in 2023, then rose 21.56% in 2024.
  • Iradimed's Invested Capital stood at $72.2 million in 2021, then grew by 2.08% to $73.7 million in 2022, then decreased by 3.06% to $71.4 million in 2023, then rose by 21.56% to $86.8 million in 2024, then increased by 13.28% to $98.4 million in 2025.
  • Per Business Quant, the three most recent readings for IRMD's Invested Capital are $98.4 million (Q3 2025), $94.3 million (Q2 2025), and $90.1 million (Q1 2025).